|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
8 January 2018 |
|
Main ID: |
NCT02269878 |
|
Date of registration:
|
11/10/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma
|
|
Scientific title:
|
The Effect of FAS and FAS Ligand Genetic Polymorphisms on the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Platinum-Based Regimens |
|
Date of first enrolment:
|
April 2014 |
|
Target sample size:
|
68 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02269878 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Egypt
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients with histologically confirmed Malignant Pleural Mesothelioma
- Age of 18 years or more.
- first-line chemotherapy with platinum-Based agents
Exclusion Criteria:
- history of prior malignancy.
- pregnancy or lactation or any other reason preventing him from taking platinum-Based
chemotherapy (AST more than 2.5* Upper Limit of Normal or Serum bilirubin more than
1.5* Upper Limit of Normal)
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Malignant Pleural Mesothelioma
|
|
Primary Outcome(s)
|
|
response rate
[Time Frame: After 6 cycles of chemotherapy (each cycle is 21 days )]
|
|
Secondary Outcome(s)
|
|
overall survival (OS)
[Time Frame: one year]
|
|
estimation of treatment related toxicity
[Time Frame: during the chemotherapy period, average duration 4 months]
|
|
progression free survival (PFS)
[Time Frame: one year]
|
|
Secondary ID(s)
|
|
Master (No14)
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|